Literature DB >> 28706906

Mesothelioma: recent highlights.

Michele Carbone1, Haining Yang1.   

Abstract

Recent discoveries have elucidated some of the mechanisms responsible for the development of mesothelioma. These discoveries are: (I) the critical role of chronic inflammation in promoting mesothelioma growth, driven by the release of high mobility group box protein-1 (HMGB1) following asbestos deposition in tissues and its potential role as a biomarker to identify asbestos exposed individuals and mesothelioma patients; (II) the discovery that inherited heterozygous germline mutations of the deubiquitylase BRCA-associated protein 1 (BAP1) cause a high incidence of mesothelioma in some families; and that (III) germline BAP1 mutations lower the threshold of asbestos required to cause mesothelioma in mice, evidence of gene X environment interaction. These findings together with the identification of novel serum biomarkers, including HMGB1, Fibulin-3, etc., promise to revolutionize screening and treatment of this malignancy in the coming years.

Entities:  

Keywords:  BRCA-associated protein 1 (BAP1); Mesothelioma; SV40; asbestos; erionite; high mobility group box protein-1 (HMGB1)

Year:  2017        PMID: 28706906      PMCID: PMC5497108          DOI: 10.21037/atm.2017.04.29

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  54 in total

1.  Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey.

Authors:  I Roushdy-Hammady; J Siegel; S Emri; J R Testa; M Carbone
Journal:  Lancet       Date:  2001-02-10       Impact factor: 79.321

2.  Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province.

Authors:  J C WAGNER; C A SLEGGS; P MARCHAND
Journal:  Br J Ind Med       Date:  1960-10

3.  Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma.

Authors:  Michele Carbone; Haining Yang
Journal:  Clin Cancer Res       Date:  2011-11-07       Impact factor: 12.531

4.  High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma.

Authors:  Yoshie Yoshikawa; Mitsuru Emi; Tomoko Hashimoto-Tamaoki; Masaki Ohmuraya; Ayuko Sato; Tohru Tsujimura; Seiki Hasegawa; Takashi Nakano; Masaki Nasu; Sandra Pastorino; Agata Szymiczek; Angela Bononi; Mika Tanji; Ian Pagano; Giovanni Gaudino; Andrea Napolitano; Chandra Goparaju; Harvey I Pass; Haining Yang; Michele Carbone
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-09       Impact factor: 11.205

5.  Genetic predisposition to fiber carcinogenesis causes a mesothelioma epidemic in Turkey.

Authors:  A Umran Dogan; Y Izzettin Baris; Meral Dogan; Salih Emri; Ian Steele; Amira G Elmishad; Michele Carbone
Journal:  Cancer Res       Date:  2006-05-15       Impact factor: 12.701

6.  Inflammation precedes the development of human malignant mesotheliomas in a SCID mouse xenograft model.

Authors:  Jedd M Hillegass; Arti Shukla; Sherrill A Lathrop; Maximilian B MacPherson; Stacie L Beuschel; Kelly J Butnor; Joseph R Testa; Harvey I Pass; Michele Carbone; Chad Steele; Brooke T Mossman
Journal:  Ann N Y Acad Sci       Date:  2010-08       Impact factor: 5.691

7.  Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003-2008.

Authors:  S Jane Henley; Theodore C Larson; Manxia Wu; Vinicius C S Antao; Mary Lewis; Germania A Pinheiro; Christie Eheman
Journal:  Int J Occup Environ Health       Date:  2013 Jan-Mar

8.  A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma.

Authors:  K A W Wadt; L G Aoude; P Johansson; A Solinas; A Pritchard; O Crainic; M T Andersen; J F Kiilgaard; S Heegaard; L Sunde; B Federspiel; J Madore; J F Thompson; S W McCarthy; A Goodwin; H Tsao; G Jönsson; K Busam; R Gupta; J M Trent; A-M Gerdes; K M Brown; R A Scolyer; N K Hayward
Journal:  Clin Genet       Date:  2014-11-06       Impact factor: 4.438

9.  Germline BAP1 mutations predispose to malignant mesothelioma.

Authors:  Joseph R Testa; Mitchell Cheung; Jianming Pei; Jennifer E Below; Yinfei Tan; Eleonora Sementino; Nancy J Cox; A Umran Dogan; Harvey I Pass; Sandra Trusa; Mary Hesdorffer; Masaki Nasu; Amy Powers; Zeyana Rivera; Sabahattin Comertpay; Mika Tanji; Giovanni Gaudino; Haining Yang; Michele Carbone
Journal:  Nat Genet       Date:  2011-08-28       Impact factor: 38.330

10.  BAP1 loss defines a new class of renal cell carcinoma.

Authors:  Samuel Peña-Llopis; Silvia Vega-Rubín-de-Celis; Arnold Liao; Nan Leng; Andrea Pavía-Jiménez; Shanshan Wang; Toshinari Yamasaki; Leah Zhrebker; Sharanya Sivanand; Patrick Spence; Lisa Kinch; Tina Hambuch; Suneer Jain; Yair Lotan; Vitaly Margulis; Arthur I Sagalowsky; Pia Banerji Summerour; Wareef Kabbani; S W Wendy Wong; Nick Grishin; Marc Laurent; Xian-Jin Xie; Christian D Haudenschild; Mark T Ross; David R Bentley; Payal Kapur; James Brugarolas
Journal:  Nat Genet       Date:  2012-06-10       Impact factor: 38.330

View more
  18 in total

1.  From keyhole to sandwich: change in laparoscopic repair of parastomal hernias at a single centre.

Authors:  C Bertoglio; L Morini; M Maspero; A Zironda; B Alampi; M Mazzola; C Magistro; G Ferrari
Journal:  Surg Endosc       Date:  2020-04-27       Impact factor: 4.584

2.  Silencing VDAC1 to Treat Mesothelioma Cancer: Tumor Reprograming and Altering Tumor Hallmarks.

Authors:  Swaroop Kumar Pandey; Renen Machlof-Cohen; Manikandan Santhanam; Anna Shteinfer-Kuzmine; Varda Shoshan-Barmatz
Journal:  Biomolecules       Date:  2022-06-27

Review 3.  New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma.

Authors:  Marika Rossini; Paola Rizzo; Ilaria Bononi; Anthony Clementz; Roberto Ferrari; Fernanda Martini; Mauro G Tognon
Journal:  Front Oncol       Date:  2018-04-03       Impact factor: 6.244

4.  Asbestos and Mesothelioma: A Comment.

Authors:  Sergei V Jargin
Journal:  Indian J Occup Environ Med       Date:  2018 May-Aug

5.  Dropwort-induced metabolic reprogramming restrains YAP/TAZ/TEAD oncogenic axis in mesothelioma.

Authors:  Claudio Pulito; Etleva Korita; Andrea Sacconi; Mariacristina Valerio; Luca Casadei; Federica Lo Sardo; Federica Mori; Maria Ferraiuolo; Giuseppe Grasso; Anna Maidecchi; Jacopo Lucci; Marius Sudol; Paola Muti; Giovanni Blandino; Sabrina Strano
Journal:  J Exp Clin Cancer Res       Date:  2019-08-09

Review 6.  Biocompatibility and Carcinogenicity of Carbon Nanotubes as Biomaterials.

Authors:  Kaoru Aoki; Naoto Saito
Journal:  Nanomaterials (Basel)       Date:  2020-02-04       Impact factor: 5.076

Review 7.  HMGB1 as a therapeutic target in disease.

Authors:  Jiaming Xue; Joelle S Suarez; Michael Minaai; Shuangjing Li; Giovanni Gaudino; Harvey I Pass; Michele Carbone; Haining Yang
Journal:  J Cell Physiol       Date:  2020-10-26       Impact factor: 6.384

Review 8.  Mouse models for mesothelioma drug discovery and development.

Authors:  Kenneth P Seastedt; Nathanael Pruett; Chuong D Hoang
Journal:  Expert Opin Drug Discov       Date:  2020-12-31       Impact factor: 7.050

9.  Detecting germline BAP1 mutations in patients with peritoneal mesothelioma: benefits to patient and family members.

Authors:  Muaiad Kittaneh; Charles Berkelhammer
Journal:  J Transl Med       Date:  2018-07-13       Impact factor: 5.531

10.  Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro.

Authors:  Sabrina Borchert; Michael Wessolly; Jan Schmeller; Elena Mairinger; Jens Kollmeier; Thomas Hager; Thomas Mairinger; Thomas Herold; Daniel C Christoph; Robert F H Walter; Wilfried E E Eberhardt; Till Plönes; Jeremias Wohlschlaeger; Clemens Aigner; Kurt Werner Schmid; Fabian D Mairinger
Journal:  BMC Cancer       Date:  2019-01-30       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.